Genetic Testing in Brugada Syndrome: A 30-Year Experience
Luigi Pannone,Antonio Bisignani,Randy Osei,Anaïs Gauthey,Antonio Sorgente,Cinzia Monaco,Domenico Giovanni Della Rocca,Alvise Del Monte,Antanas Strazdas,Joerelle Mojica,Maysam Al Housari,Vincenzo Miraglia,Sahar Mouram,Giampaolo Vetta,Gaetano Paparella,Robbert Ramak,Ingrid Overeinder,Gezim Bala,Alexandre Almorad,Erwin Ströker,Gudrun Pappaert,Juan Sieira,Thomy de Ravel,Mark La Meir,Andrea Sarkozy,Pedro Brugada,Gian Battista Chierchia,Sonia Van Dooren,Carlo de Asmundis
DOI: https://doi.org/10.1161/circep.123.012374
2024-03-03
Circulation Arrhythmia and Electrophysiology
Abstract:Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:A pathogenic/likely pathogenic variant can be found in 20% to 25% of patients with Brugada syndrome (BrS) and a pathogenic/likely pathogenic variant in SCN5A is associated with a worse prognosis. The aim of this study is to define the diagnostic yield of a large gene panel with ACMG variant classification and to assess prognosis of SCN5A and non-SCN5A variants.METHODS:All patients with BrS, were prospectively enrolled in the UZB registry between 1992 and 2022. Inclusion criteria for the study were (1) BrS diagnosis; (2) genetic analysis performed with a large gene panel; (3) classification of variants following ACMG guidelines. Patients with a pathogenic/likely pathogenic variant in SCN5A were defined as SCN5A+. Patients with a reported variant in anon-SCN5Agene or with no reported variants were defined as patients with SCN5A−. All variants were classified as missense or predicted loss of function.RESULTS:A total of 500 BrS patients were analyzed. A total of 104 patients (20.8%) were SCN5A+and 396 patients (79.2%) were SCN5A−. Anon-SCN5Agene variant was found in 75 patients (15.0%), of whom, 58 patients (77.3%) had a missense variant and 17 patients (22.7%) had a predicted loss of function variant. At a follow-up of 84.0 months, 48 patients (9.6%) experienced a ventricular arrhythmia (VA). Patients without any variant had higher VA-free survival, compared with carriers of a predicted loss of function variant inSCN5A+ornon-SCN5Agenes. There was no difference in VA-free survival between patients without any variant and missense variant carriers inSCN5A+ornon-SCN5Agenes. At Cox analysis, SCN5A+or non-SCN5A predicted loss of function variant was an independent predictor of VA.CONCLUSIONS:In a large BrS cohort, the yield for SCN5A+is 20.8%. A predicted loss of function variant carrier is an independent predictor of VA.
cardiac & cardiovascular systems